Cargando…

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines

Gemcitabine and paclitaxel are active agents in the treatment of non-small-cell lung cancer (NSCLC). To optimize treatment drug combinations, simultaneously and 4 and 24 h intervals, were studied using DNA flow cytometry and multiple drug effect analysis in the NSCLC cell lines H460, H322 and Lewis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroep, J R, Giaccone, G, Tolis, C, Voorn, D A, Loves, W J P, Groeningen, C J van, Pinedo, H M, Peters, G J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363564/ https://www.ncbi.nlm.nih.gov/pubmed/10993656 http://dx.doi.org/10.1054/bjoc.2000.1399

Ejemplares similares

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
por: Moorsel, C J A van, et al.
Publicado: (1999)

Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines
por: Bergman, A M, et al.
Publicado: (2003)

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study
por: Douillard, J Y, et al.
Publicado: (2001)

Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.
por: Liebmann, J. E., et al.
Publicado: (1993)

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines
por: Valdez, B C, et al.
Publicado: (2014)

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines
por: Han, E Kyu-Ho, et al.
Publicado: (2000)

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer
por: van Zweeden, A. A., et al.
Publicado: (2018)

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer
por: Zoli, W, et al.
Publicado: (1999)

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
por: Comella, P, et al.
Publicado: (2004)

Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines
por: Affram, Kevin, et al.
Publicado: (2015)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
por: Engblom, P, et al.
Publicado: (1999)

Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer
por: Barlow, C, et al.
Publicado: (2004)

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
por: Beretta, G D, et al.
Publicado: (2000)

Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines
por: Effendi, Wiwin Is, et al.
Publicado: (2019)

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
por: van Putten, J W G, et al.
Publicado: (2000)

Honokiol Arrests Cell Cycle, Induces Apoptosis, and Potentiates the Cytotoxic Effect of Gemcitabine in Human Pancreatic Cancer Cells
por: Arora, Sumit, et al.
Publicado: (2011)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
por: Gridelli, C, et al.
Publicado: (2000)

Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012)

Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
por: Earle, C C, et al.
Publicado: (1999)

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
por: Somlo, G, et al.
Publicado: (2001)

Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3
por: Baker, A H, et al.
Publicado: (1999)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer
por: Rischin, D, et al.
Publicado: (2000)

Human oesophageal adenocarcinoma cell lines JROECL 47 and JROECL 50 are admixtures of the human colon carcinoma cell line HCT 116
por: Wijnhoven, B P L, et al.
Publicado: (2000)

Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma
por: Mulatero, C, et al.
Publicado: (2000)

Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes
por: Spierings, D C J, et al.
Publicado: (2000)

Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas
por: Cruz, I, et al.
Publicado: (1999)

DAP3-mediated cell cycle regulation and its association with radioresistance in human lung adenocarcinoma cell lines
por: Sato, Yoshiaki, et al.
Publicado: (2023)

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
por: Anderson, H, et al.
Publicado: (2000)

Evaluation of a Gemcitabine‐Doxorubicin‐Paclitaxel Combination Schedule through Flow Cytometry Assessment of Apoptosis Extent Induced in Human Breast Cancer Cell Lines
por: Serrano, Maria J., et al.
Publicado: (2002)

Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase
por: Wang, X, et al.
Publicado: (1999)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
por: Jagdev, S P, et al.
Publicado: (2001)

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer
por: Sørensen, J B, et al.
Publicado: (1999)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Bisphosphonates induce apoptosis in human breast cancer cell lines
por: Senaratne, S G, et al.
Publicado: (2000)

Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel
por: Lin, H-L, et al.
Publicado: (1999)

TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe
por: Tanière, P, et al.
Publicado: (2001)

Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial
por: Kooten, M Van, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_t80kq1ron0o14h0d4ks76sbnad